Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Thursday, Marketbeat reports. The firm issued a neutral rating on the stock.

Avalo Therapeutics Trading Up 13.6 %

Avalo Therapeutics stock opened at $13.20 on Thursday. The stock has a 50 day moving average of $9.36 and a 200-day moving average of $11.25. Avalo Therapeutics has a 52 week low of $3.95 and a 52 week high of $34.46.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). On average, analysts forecast that Avalo Therapeutics will post -7.78 earnings per share for the current year.

Institutional Trading of Avalo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AVTX. Affinity Asset Advisors LLC bought a new position in Avalo Therapeutics during the 1st quarter worth approximately $218,000. Ikarian Capital LLC bought a new position in Avalo Therapeutics during the first quarter worth $1,015,000. Finally, Logos Global Management LP acquired a new position in Avalo Therapeutics in the second quarter worth $6,722,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.